Target intelligence / Profile preview

Myosin light chain 1, skeletal muscle isoform (MYL1)

Target
MYL1
Molecular classification
Other (structural protein, motor protein subunit), EF-hand protein family (calcium-binding protein superfamily), Alkali light chain (essential light chain)
01

Overview

Myosin light chain 1, skeletal muscle isoform (MYL1) is a non-regulatory “essential” (alkali) light chain expressed predominantly in fast skeletal muscle[1][3][7]. It is part of the myosin hexameric complex: two heavy chains, two essential (alkali) light chains, and two regulatory light chains[1][3][4]. MYL1 binds to the IQ1 motif on the myosin heavy chain neck region, stabilizing the structure and contributing to muscle contraction by modulating the ATPase activity of the entire complex[4][6]. MYL1 is necessary for proper muscle fiber formation and maintenance[1][7]; defects in MYL1 can lead to congenital myopathies characterized by muscle weakness and structural abnormalities[1][5]. As a member of the EF-hand family, it contains calcium-binding motifs but is classified as non-regulatory, with its function focused on structural integrity and modulation of force rather than direct signal transduction[4][6]. There are no drugs that specifically target MYL1, and it is not considered a conventional therapeutic target like a receptor or enzyme[1][4][7].

Other names
Myosin light chain 1/3, skeletal muscle isoformMLC1MLC3MLC1FMLC3FMyosin light chain A1/A2MLC-1MLC1/3Myosin light chain alkali 1/2CMYO14CMYP14MYOFTAmyosin, light chain 1, alkaliskeletal, fastmyosin, light polypeptide 1, alkali
02

Biological functions

Structural constituent of muscleMaintenance and formation of myofibersSkeletal muscle contractionActin-myosin ATPase activity (component of myosin motor complex)Modulator of force transduction and cross-bridge kinetics
03

Disease associations

Congenital myopathy (Congenital myopathy 14, Congenital myopathy with reduced type 2 muscle fibers)Other myopathies and muscle function disorders
04

Safety considerations

Alterations or mutations may cause muscle weakness or myopathic conditions; no direct pharmacological safety concerns reported as it is not an established drug target
05

Biomarkers

Mutation or deficiency can serve as a biomarker for specific congenital myopathies

Beyond the preview

Go deeper on Myosin light chain 1, skeletal muscle isoform (MYL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myosin light chain 1, skeletal muscle isoform (MYL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call